Clinical outcomes for metastatic renal cell carcinoma (mRCC) patients ineligible for front-line clinical trials

Researchers investigated the clinical outcomes in a real-world cohort of patients who would not have met the criteria for inclusion in front-line mRCC trials due to extensive inclusion and exclusion criteria. Sixty-two patients treated with axitinib/pembrolizumab and 103 treated with ipilimumab/nivolumab were identified. Of the 24 patients in the axitinib/pembrolizumab cohort who were found to be clinical trial ineligible (CTI), the major reasons for the ineligibility were lab abnormalities (n = 11), histology (n = 9), and brain metastases (n = 3). Of the 59 patients in the ipilimumab/nivolumab cohort who were CTI, the most common reasons for ineligibility were brain metastases (n = 18), lab abnormalities (n = 16), and histology (n = 16). It was found that the median progression-free survival and overall survival was higher for the patients who were clinical trial eligible CTE than the CTI patients.